Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Marvell Technology Inc (MRVL) vs Revvity Inc (RVTY) Price & Performance

Marvell Technology IncTrade
Revvity IncTrade

Price performance (Past 24H)

Key statistics

Marvell Technology Inc vs Revvity Inc — how do they compare? Marvell Technology Inc trades at $274.71 (market cap $246.84B), while Revvity Inc trades at $154.1 (market cap $16.98B). The key difference: Marvell Technology Inc is far larger — about 14.5× Revvity Inc's market cap, and Revvity Inc pays the higher dividend (0.18%). Which is the better fit depends on your goals — on Pluang, investors hold Marvell Technology Inc for 42 Days and Revvity Inc for 12 Days on average.

MRVLRVTY
Market Cap
$246.84B$16.98B
Volume
29,003,8301,456,900
Sector
TechnologyHealth
52-Week High
$316.43$157.36
52-Week Low
$73.73$82.26
Typical Hold Time
42 Days12 Days
Enterprise Value
$248.19B$19.30B
Dividend Yield
0.09%0.18%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Marvell Technology Inc

Marvell Technology (MRVL) trades at $275.28, down 3.3% in the last session, but maintains strong technical momentum with bullish moving averages and support at $267. The company has beaten earnings estimates for three consecutive quarters, with Q3 2026 EPS expected at $1.1. Revenue growth accelerated to 42% in fiscal 2026, driven by data center products comprising 74% of sales. Analyst consensus remains overwhelmingly bullish with 84% buy ratings and a $327.86 price target, representing 19% upside potential.

Marvell's AI-driven growth story appears compelling with custom chip deals with hyperscalers potentially generating $120 billion in cumulative revenue. However, high valuation multiples (P/E 90.95, P/S 25.77) and recent net losses (-$885M in 2025) present risks. The stock's 210% YTD gain suggests much optimism is priced in, requiring continued execution on the $18 billion fiscal 2028 revenue guidance to justify current levels.

Revvity Inc

RVTY trades at $155.01, up 0.92% with a bullish technical outlook. The stock shows strong earnings momentum with three consecutive quarterly beats and maintains solid profitability with 54.98% gross margins. Recent developments include new product launches in Europe and strategic acquisitions to expand metabolic disease research capabilities.

The investment case balances premium valuation (P/E 73.15) against consistent execution and growth initiatives. Key risks include China market pressures and margin compression, while analyst consensus remains positive with 52% buy ratings. Upside potential exists if Q3 earnings meet expectations in November.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

MRVL
68% Buy32% Sell
Avg holding period · 42 Days
RVTY
0% Buy100% Sell
Avg holding period · 12 Days

Top news

Latest headlines on both assets

About Marvell Technology Inc

Marvell Technology is a leading fabless chipmaker focused on networking and storage applications. Marvell serves the data center, carrier, enterprise, automotive, and consumer end markets with processors, optical interconnections, application-specific integrated circuits (ASICs), and merchant silicon for Ethernet applications. The firm is an active acquirer, with five large acquisitions since 2017 helping it pivot out of legacy consumer applications to focus on the cloud and 5G markets.

Read more on MRVL →

About Revvity Inc

Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.

Read more on RVTY →